ConductScience.org, home

Paper38102001

Harnessing the potential of CD40 agonism in cancer therapy.

Zhou Y and 2 others. Cytokine Growth Factor Rev, 2024. Cited by 51 papers, by iCite.

Cite this record

ConductScience Library. Harnessing the potential of CD40 agonism in cancer therapy. Papers, record 38102001. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38102001

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Harnessing the potential of CD40 agonism in cancer therapy.
PubMed
Journal
Cytokine Growth Factor Rev
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
51
iCite
Relative citation ratio, by iCite
6.32, provisional
iCite
Revised in PubMed
2025-02-02
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou YYang
2Richmond AAnn
3Yan CChi

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CD40 AntigensMajor topic
NeoplasmsMajor topic
Humans
CD40 Ligand
T-Lymphocytes
Cytokines

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
I01 BX002301BLRD VAUnited StatesI01BX002301PubMed and NIHNIH RePORTER
IK6 BX005225BLRD VAUnited StatesIK6BX005225PubMed and NIHNIH RePORTER
R01 CA116021NCI NIH HHSUnited StatesR01CA116021PubMed and NIHNIH RePORTER
R01 CA243326NCI NIH HHSUnited StatesR01CA243326PubMed and NIHNIH RePORTER

Download CSV of grants

References145

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17539000Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis.J Biol Chem1995https://conductscience.org/library/papers/7539000PubMed
27730613Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells.J Immunol1995https://conductscience.org/library/papers/7730613PubMed
37595225CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.J Exp Med1995https://conductscience.org/library/papers/7595225PubMed
419118532Mechanisms of LPS-induced CD40 expression in human peripheral blood monocytic cells.Biochem Biophys Res Commun2009https://conductscience.org/library/papers/19118532PubMed
515209378PI3K signaling controls cell fate at many points in B lymphocyte development and activation.Semin Cell Dev Biol2004https://conductscience.org/library/papers/15209378PubMed
635292514The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.J Immunother Cancer2022https://conductscience.org/library/papers/35292514PubMed
734092233Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.Mol Cancer2021https://conductscience.org/library/papers/34092233PubMed
88626375Human native soluble CD40L is a biologically active trimer, processed inside microsomes.J Biol Chem1996https://conductscience.org/library/papers/8626375PubMed
910096561Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis.Cancer Res1999https://conductscience.org/library/papers/10096561PubMed
1032583318Beyond Antibodies: The DARPin® Drug Platform.BioDrugs2020https://conductscience.org/library/papers/32583318PubMed
1137509357Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.Cancers (Basel)2023https://conductscience.org/library/papers/37509357PubMed
1222421945Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.J Immunother2012https://conductscience.org/library/papers/22421945PubMed
1324189063CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner.J Biol Chem2013https://conductscience.org/library/papers/24189063PubMed
1411825564A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas.Immunity2002https://conductscience.org/library/papers/11825564PubMed
1518548529Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis.Cancer2008https://conductscience.org/library/papers/18548529PubMed
1631555278TRIM21-From Intracellular Immunity to Therapy.Front Immunol2019https://conductscience.org/library/papers/31555278PubMed
177514045Inhibition of human B-cell lymphoma growth by CD40 stimulation.Blood1994https://conductscience.org/library/papers/7514045PubMed
1837270599CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth.Mol Cancer2023https://conductscience.org/library/papers/37270599PubMed
1935190724Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.Nat Cancer2022https://conductscience.org/library/papers/35190724PubMed
2015879094CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.J Immunol2005https://conductscience.org/library/papers/15879094PubMed

See all 145 referencesDownload CSV of references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.

PMIDTitleJournalYearIn PapersSource
42706236B cells in cancer: functions, mechanisms and therapeutic advances.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42706236PubMed
42630934B-cells in breast cancer: current insights and challenges.Front Oncol2026https://conductscience.org/library/papers/42630934PubMed
42548768Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses.Cancer Innov2026https://conductscience.org/library/papers/42548768PubMed
42499227CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice.Pigment Cell Melanoma Res2026https://conductscience.org/library/papers/42499227PubMed
42498930Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics.J Transl Med2026https://conductscience.org/library/papers/42498930PubMed
42370186TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives.Theranostics2026https://conductscience.org/library/papers/42370186PubMed
42353028CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL.Int J Mol Sci2026https://conductscience.org/library/papers/42353028PubMed
42292487The CD40-CD154 axis in transplantation: from immunobiology to therapeutic targeting.Front Immunol2026https://conductscience.org/library/papers/42292487PubMed
42279326CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.Cancers (Basel)2026https://conductscience.org/library/papers/42279326PubMed
42233099Targeting tumor-associated macrophages in pancreatic cancer.ILIVER2026https://conductscience.org/library/papers/42233099PubMed
42218726Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Clin Exp Med2026https://conductscience.org/library/papers/42218726PubMed
42164656Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies.MedComm (2020)2026https://conductscience.org/library/papers/42164656PubMed
42121263Metabolic pattern changes of macrophages during cancer development and progression.J Transl Med2026https://conductscience.org/library/papers/42121263PubMed
42067655
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study.
Nat Cancer2026https://conductscience.org/library/papers/42067655PubMed
42001092Actomyosin rings constrain CD40 mobility to organize the dendritic cell immunological synapse.Cell Commun Signal2026https://conductscience.org/library/papers/42001092PubMed
41988365
T‑Cell Immunoreceptor with Ig and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains/Cluster of Differentiation 40 Cellular Nanovesicles Carrying Oxaliplatin Exhibited Superior Pancreatic Cancer Cells Therapy.
ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/41988365PubMed
41609852Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41609852PubMed
41526341RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance.Nat Commun2026https://conductscience.org/library/papers/41526341PubMed
41375696The Effect of T Regulatory Cell Infiltration on Survival Outcomes in Metastatic Pancreatic Cancer Patients with a Review of Immunobiology, Prognostic Value and Future Therapeutic Options.J Clin Med2025https://conductscience.org/library/papers/41375696PubMed
41335396Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.Mol Biomed2025https://conductscience.org/library/papers/41335396PubMed

See all 38 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD40958PubTator's text mininghttps://conductscience.org/library/genes/958NCBI Gene
CD40LG959PubTator's text mininghttps://conductscience.org/library/genes/959NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38102001

GET https://conductscience.org/api/papers/v1/38102001/references?page=2